Radiation Dose and Fractionation for Limited-stage Small-cell Lung Cancer: Survey of US Radiation Oncologists on Practice Patterns

Matthew J. Farrell, Jehan B. Yahya, Catherine Degnin, Yiyi Chen, John Holland, Mark A. Henderson, Jerry Jaboin, Matthew M. Harkenrider, Charles Thomas, Timur Mitin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Thoracic radiotherapy (TRT) with concurrent chemotherapy is standard for limited-stage small-cell lung cancer (LS-SCLC). However, the optimal dosing and fractionation remain unclear. The National Comprehensive Cancer Network guidelines have recommended either 45 Gy delivered twice daily (BID) or 60 to 70 Gy delivered once daily (QD). However, the current practice patterns among US radiation oncologists are unknown. Materials and Methods: We surveyed US radiation oncologists using an institutional review board-approved questionnaire. The questions covered demographic data, self-rated knowledge of key trials, and treatment recommendations. Results: We received 309 responses from radiation oncologists. Of the 309 radiation oncologists, 60% preferred TRT QD and 76% acknowledged QD to be more common in their practice. The respondents in academic settings were more likely to endorse BID treatment by both preference (P =.001) and actual practice (P =.009). The concordance between preferring QD and administering QD in practice was 100%. In contrast, 40% of respondents who preferred BID actually administered QD more often. Also, 15% of physicians would be unwilling to switch from QD to BID and 3% would be unwilling to switch from BID to QD, even on patient request. Most respondents (88%) recommended a dose of 45 Gy for BID treatment. For QD treatment, the division was greater, with 54% recommending 60 Gy, 30% recommending 63 to 66 Gy, and 10% recommending 70 Gy. Conclusion: Substantial variation exists in how US radiation oncologists approach TRT dosing and fractionation for LS-SCLC. Three quarters of our respondents reported administering TRT QD most often. The most common doses were 60 Gy QD and 45 Gy BID. The results of the present survey have provided the most up-to-date information on US practice patterns for LS-SCLC. In the present survey of 309 US radiation oncologists on how they treat limited-stage small-cell lung cancer, substantial variation was found in the dosing and fractionation for thoracic radiotherapy (TRT). Three quarters of the respondents administered once-daily TRT more commonly than twice daily. For twice-daily TRT, most preferred a dose of 45 Gy. For once-daily TRT, the disagreement was greater, with a 60-Gy dose the most common.

Original languageEnglish (US)
JournalClinical Lung Cancer
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Dose Fractionation
Small Cell Lung Carcinoma
Radiotherapy
Thorax
Radiation
Radiation Oncologists
Surveys and Questionnaires
Research Ethics Committees
Therapeutics
Demography
Guidelines
Physicians
Drug Therapy

Keywords

  • Dose escalation
  • Dosing
  • Hyperfractionated
  • LS-SCLC
  • Thoracic radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Radiation Dose and Fractionation for Limited-stage Small-cell Lung Cancer : Survey of US Radiation Oncologists on Practice Patterns. / Farrell, Matthew J.; Yahya, Jehan B.; Degnin, Catherine; Chen, Yiyi; Holland, John; Henderson, Mark A.; Jaboin, Jerry; Harkenrider, Matthew M.; Thomas, Charles; Mitin, Timur.

In: Clinical Lung Cancer, 01.01.2018.

Research output: Contribution to journalArticle

@article{63288fa222c54b51800388bf45d15058,
title = "Radiation Dose and Fractionation for Limited-stage Small-cell Lung Cancer: Survey of US Radiation Oncologists on Practice Patterns",
abstract = "Background: Thoracic radiotherapy (TRT) with concurrent chemotherapy is standard for limited-stage small-cell lung cancer (LS-SCLC). However, the optimal dosing and fractionation remain unclear. The National Comprehensive Cancer Network guidelines have recommended either 45 Gy delivered twice daily (BID) or 60 to 70 Gy delivered once daily (QD). However, the current practice patterns among US radiation oncologists are unknown. Materials and Methods: We surveyed US radiation oncologists using an institutional review board-approved questionnaire. The questions covered demographic data, self-rated knowledge of key trials, and treatment recommendations. Results: We received 309 responses from radiation oncologists. Of the 309 radiation oncologists, 60{\%} preferred TRT QD and 76{\%} acknowledged QD to be more common in their practice. The respondents in academic settings were more likely to endorse BID treatment by both preference (P =.001) and actual practice (P =.009). The concordance between preferring QD and administering QD in practice was 100{\%}. In contrast, 40{\%} of respondents who preferred BID actually administered QD more often. Also, 15{\%} of physicians would be unwilling to switch from QD to BID and 3{\%} would be unwilling to switch from BID to QD, even on patient request. Most respondents (88{\%}) recommended a dose of 45 Gy for BID treatment. For QD treatment, the division was greater, with 54{\%} recommending 60 Gy, 30{\%} recommending 63 to 66 Gy, and 10{\%} recommending 70 Gy. Conclusion: Substantial variation exists in how US radiation oncologists approach TRT dosing and fractionation for LS-SCLC. Three quarters of our respondents reported administering TRT QD most often. The most common doses were 60 Gy QD and 45 Gy BID. The results of the present survey have provided the most up-to-date information on US practice patterns for LS-SCLC. In the present survey of 309 US radiation oncologists on how they treat limited-stage small-cell lung cancer, substantial variation was found in the dosing and fractionation for thoracic radiotherapy (TRT). Three quarters of the respondents administered once-daily TRT more commonly than twice daily. For twice-daily TRT, most preferred a dose of 45 Gy. For once-daily TRT, the disagreement was greater, with a 60-Gy dose the most common.",
keywords = "Dose escalation, Dosing, Hyperfractionated, LS-SCLC, Thoracic radiotherapy",
author = "Farrell, {Matthew J.} and Yahya, {Jehan B.} and Catherine Degnin and Yiyi Chen and John Holland and Henderson, {Mark A.} and Jerry Jaboin and Harkenrider, {Matthew M.} and Charles Thomas and Timur Mitin",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.cllc.2018.08.015",
language = "English (US)",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",

}

TY - JOUR

T1 - Radiation Dose and Fractionation for Limited-stage Small-cell Lung Cancer

T2 - Survey of US Radiation Oncologists on Practice Patterns

AU - Farrell, Matthew J.

AU - Yahya, Jehan B.

AU - Degnin, Catherine

AU - Chen, Yiyi

AU - Holland, John

AU - Henderson, Mark A.

AU - Jaboin, Jerry

AU - Harkenrider, Matthew M.

AU - Thomas, Charles

AU - Mitin, Timur

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Thoracic radiotherapy (TRT) with concurrent chemotherapy is standard for limited-stage small-cell lung cancer (LS-SCLC). However, the optimal dosing and fractionation remain unclear. The National Comprehensive Cancer Network guidelines have recommended either 45 Gy delivered twice daily (BID) or 60 to 70 Gy delivered once daily (QD). However, the current practice patterns among US radiation oncologists are unknown. Materials and Methods: We surveyed US radiation oncologists using an institutional review board-approved questionnaire. The questions covered demographic data, self-rated knowledge of key trials, and treatment recommendations. Results: We received 309 responses from radiation oncologists. Of the 309 radiation oncologists, 60% preferred TRT QD and 76% acknowledged QD to be more common in their practice. The respondents in academic settings were more likely to endorse BID treatment by both preference (P =.001) and actual practice (P =.009). The concordance between preferring QD and administering QD in practice was 100%. In contrast, 40% of respondents who preferred BID actually administered QD more often. Also, 15% of physicians would be unwilling to switch from QD to BID and 3% would be unwilling to switch from BID to QD, even on patient request. Most respondents (88%) recommended a dose of 45 Gy for BID treatment. For QD treatment, the division was greater, with 54% recommending 60 Gy, 30% recommending 63 to 66 Gy, and 10% recommending 70 Gy. Conclusion: Substantial variation exists in how US radiation oncologists approach TRT dosing and fractionation for LS-SCLC. Three quarters of our respondents reported administering TRT QD most often. The most common doses were 60 Gy QD and 45 Gy BID. The results of the present survey have provided the most up-to-date information on US practice patterns for LS-SCLC. In the present survey of 309 US radiation oncologists on how they treat limited-stage small-cell lung cancer, substantial variation was found in the dosing and fractionation for thoracic radiotherapy (TRT). Three quarters of the respondents administered once-daily TRT more commonly than twice daily. For twice-daily TRT, most preferred a dose of 45 Gy. For once-daily TRT, the disagreement was greater, with a 60-Gy dose the most common.

AB - Background: Thoracic radiotherapy (TRT) with concurrent chemotherapy is standard for limited-stage small-cell lung cancer (LS-SCLC). However, the optimal dosing and fractionation remain unclear. The National Comprehensive Cancer Network guidelines have recommended either 45 Gy delivered twice daily (BID) or 60 to 70 Gy delivered once daily (QD). However, the current practice patterns among US radiation oncologists are unknown. Materials and Methods: We surveyed US radiation oncologists using an institutional review board-approved questionnaire. The questions covered demographic data, self-rated knowledge of key trials, and treatment recommendations. Results: We received 309 responses from radiation oncologists. Of the 309 radiation oncologists, 60% preferred TRT QD and 76% acknowledged QD to be more common in their practice. The respondents in academic settings were more likely to endorse BID treatment by both preference (P =.001) and actual practice (P =.009). The concordance between preferring QD and administering QD in practice was 100%. In contrast, 40% of respondents who preferred BID actually administered QD more often. Also, 15% of physicians would be unwilling to switch from QD to BID and 3% would be unwilling to switch from BID to QD, even on patient request. Most respondents (88%) recommended a dose of 45 Gy for BID treatment. For QD treatment, the division was greater, with 54% recommending 60 Gy, 30% recommending 63 to 66 Gy, and 10% recommending 70 Gy. Conclusion: Substantial variation exists in how US radiation oncologists approach TRT dosing and fractionation for LS-SCLC. Three quarters of our respondents reported administering TRT QD most often. The most common doses were 60 Gy QD and 45 Gy BID. The results of the present survey have provided the most up-to-date information on US practice patterns for LS-SCLC. In the present survey of 309 US radiation oncologists on how they treat limited-stage small-cell lung cancer, substantial variation was found in the dosing and fractionation for thoracic radiotherapy (TRT). Three quarters of the respondents administered once-daily TRT more commonly than twice daily. For twice-daily TRT, most preferred a dose of 45 Gy. For once-daily TRT, the disagreement was greater, with a 60-Gy dose the most common.

KW - Dose escalation

KW - Dosing

KW - Hyperfractionated

KW - LS-SCLC

KW - Thoracic radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85053115916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053115916&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2018.08.015

DO - 10.1016/j.cllc.2018.08.015

M3 - Article

C2 - 30219240

AN - SCOPUS:85053115916

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

ER -